Vitamin a compound may reboot cancer drug in tough myeloma cases
NCT ID NCT06536413
First seen Apr 06, 2026 · Last updated May 25, 2026 · Updated 7 times
Summary
This study tests whether adding a vitamin A derivative (ATRA) to standard carfilzomib therapy can make the cancer respond again in people with multiple myeloma whose disease has stopped responding to carfilzomib. About 42 adults who have tried at least three prior treatments will receive the combination. The goal is to find a safe dose and see if it can shrink tumors or slow the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Neal Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Conditions
Explore the condition pages connected to this study.